Eli Lilly (LLY) has announced it's been granted a temporary restraining order to halt production of a generic version of its osteoporosis drug Evista.

According to Lilly, Teva Pharmaceuticals ( TEVA) had indicated it was ready to launch its version of Evista before outstanding patent litigation had been resolved. The U.S. District Court for the Southern District of Indiana is hearing the matter.

"We appreciate the Court issuing the temporary restraining order and look forward to completing the trial and vindicating our patent rights," said Robert A. Armitage, senior vice president and general counsel for Lilly.

It's been a busy few months for Teva in terms of generic-drug efforts. Last month, Teva announced it had received final FDA approval for a generic version of GlaxoSmithKline's ( GSK) migraine drug Imitrex, and in January it received approval for a version of Janssen's antipsychotic agent Risperdal. And in late December, the FDA granted tentative approval to market a version of AstraZeneca's ( AZN) Seroquel.

Lilly shares were recently up 6% to $29.66. Teva shares were down 0.2% to $43.16.

More from Stocks

Why Starbucks Latest Data Reveal Should Worry Investors

Why Starbucks Latest Data Reveal Should Worry Investors

Salesforce Is Hitting on All Cylinders as Shares Notch an All-Time High

Salesforce Is Hitting on All Cylinders as Shares Notch an All-Time High

Trump's Tariff Attack Hasn't Brought Pain to These Hot Stocks

Trump's Tariff Attack Hasn't Brought Pain to These Hot Stocks

Why GE's Stock Has Fallen 15% in the Last 30 Days

Why GE's Stock Has Fallen 15% in the Last 30 Days

Banks Prepare to Up Shareholder Payouts By $30 Billion

Banks Prepare to Up Shareholder Payouts By $30 Billion